CLSD.Q Share Price Performance
US$0.86
-14.29 (-94.32%)
85.7% undervalued intrinsic discount
US$6.00
Fair Value
Price US$0.86
AnalystHighTarget US$6.00
AnalystConsensusTarget US$60.00
Fair ValueUS$6.00
Share Pricen/a
Clearside Biomedical, Inc. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 6 Fair Values set on narratives written by author
CLSD.Q Community Narratives
AN
Fair Value US$6 85.7% undervalued intrinsic discount
Aging Global Population Will Boost Ocular Treatment Adoption
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value US$60 98.6% undervalued intrinsic discount
FDA Alignment And Phase 3 Trials Will Advance AMD Therapy
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
FDA Alignment And Phase 3 Trials Will Advance AMD Therapy
Key Takeaways FDA alignment on CLS-AX for wet AMD and Phase 2b outcomes may boost revenues and market leadership upon approval. Global partnerships and SCS technology expansions could enhance international market presence and revenue streams.Read more
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$60
98.6% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
38.16% p.a.
Profit Margin
23.22%
Future PE
149.46x
Price in 2028
US$65.66
Aging Global Population Will Boost Ocular Treatment Adoption
Key Takeaways Leading drug delivery technology, strong clinical results, and global partnerships could drive rapid adoption, robust licensing income, and significant revenue and margin expansion. Diversified pipeline and growing disease prevalence ensure long-term product launches, revenue diversification, and strong potential for transformative partnerships with next-generation therapy developers.Read more
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$6
85.7% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
115.15% p.a.
Profit Margin
23.22%
Future PE
68.61x
Price in 2028
US$7.59
Trending Discussion
Recently Updated Narratives
AN
FDA Alignment And Phase 3 Trials Will Advance AMD Therapy
Fair Value: US$60 98.6% undervalued intrinsic discount
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Aging Global Population Will Boost Ocular Treatment Adoption
Fair Value: US$6 85.7% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Clearside Biomedical, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -4.97
- 88.07%
- -780.90%
- -113.4%
About CLSD.Q
- Founded
- 2011
- Employees
- 32
- CEO
- WebsiteView website
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia. On November 23, 2025, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
